Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

US8552205B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Antonio J. Barbosa · Ave Maria, US
• Joerg Bentzien · White Plains, US
• Steven Richard Brunette · Ridgefield, US
• Zhidong Chen · New Milford, US
• Derek Cogan · Sandy Hook, US
• Donghong Amy Gao · Hopewell Junction, US
• Alexander Heim-Riether · Ingelheim am Rhein, DE
• Joshua Courtney Horan · Somerville, US
• Jennifer A. Kowalski · New Milford, US
• Michael David Lawlor · Seymour, US
• Rene Lemieux · Boston, US
• Weimin Liu · Sandy Hook, US
• Bryan McKibben · White Plains, US
• Craig Andrew Miller · Penfield, US
• Neil Moss · Ridgefield, US
• Matt Aaron Tschantz · Newtown, US
• Zhaoming Xiong · Brookfield, US
• Hui Yu · New Milford, US
• Yang Yu · Jinan, CN

Key dates

• Filing date: Nov 20, 2008
• Grant date: Oct 8, 2013
• Expiry date: Dec 26, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P39/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.